Canagliflozin: Efficacy and Safety in Combination with Metformin Alone or with Other Antihyperglycemic Agents in Type 2 Diabetes

Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241–1249

(2016) Sweety Agrawal et al.   DIABETES CARE

Initial Combination Therapy With Canagliflozin Plus Metformin Versus Each Component as Monotherapy for Drug-Naïve Type 2 Diabetes

(2016) Julio Rosenstock et al.   DIABETES CARE

CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM –2016 EXECUTIVE SUMMARY

(2016) Alan J. Garber et al.   Endocrine Practice

Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus

(2016) Nelson B. Watts et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects

(2016) Hiddo J. L. Heerspink et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis

(2016) Jason H Y Wu et al.   Lancet Diabetes & Endocrinology

Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus

(2015) Norm Rosenthal et al.   Annals of the New York Academy of Sciences

Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program

(2015) Ngozi Erondu et al.   DIABETES CARE

Sodium–Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport

(2015) Sunder Mudaliar et al.   DIABETES CARE

Introduction: Table 1

(2015)   DIABETES CARE

Association of Cardiometabolic Multimorbidity With Mortality

(2015) Emanuele Di Angelantonio et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2014) Silvio E. Inzucchi et al.   DIABETES CARE

Canagliflozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study

(2014) Lawrence A. Leiter et al.   DIABETES CARE

Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium–Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes

(2014) Bruce Neal et al.   DIABETES CARE

Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea

(2014) L. Ji et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone

(2014) T. Forst et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease

(2014) J.-F. Yale et al.   DIABETES OBESITY & METABOLISM

Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes

(2014) David Polidori et al.   DIABETOLOGIA

Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production

(2014) Aurora Merovci et al.   JOURNAL OF CLINICAL INVESTIGATION

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients

(2014) Ele Ferrannini et al.   JOURNAL OF CLINICAL INVESTIGATION

The role of the kidneys in glucose homeostasis in type 2 diabetes: Clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors

(2014) John P.H. Wilding   METABOLISM-CLINICAL AND EXPERIMENTAL

The Target of Metformin in Type 2 Diabetes

(2014) Ele Ferrannini   NEW ENGLAND JOURNAL OF MEDICINE

Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea

(2013) Guntram Schernthaner et al.   DIABETES CARE

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

(2013) J.-F. Yale et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial

(2013) F. J. Lavalle-González et al.   DIABETOLOGIA

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial

(2013) J. P. H. Wilding et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

(2013) William T Cefalu et al.   LANCET

Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes

(2012) J. Rosenstock et al.   DIABETES CARE

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies

(2010) The Emerging Risk Factors Collaboration   LANCET

SGLT2 inhibition — a novel strategy for diabetes treatment

(2010) Edward C. Chao et al.   NATURE REVIEWS DRUG DISCOVERY

Diabetes and obesity: therapeutic targeting and risk reduction - a complex interplay

(2009) Kevin Niswender   DIABETES OBESITY & METABOLISM

10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes

(2008) Rury R. Holman et al.   NEW ENGLAND JOURNAL OF MEDICINE